Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3903

1.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.

N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.

PMID:
26244877
2.

10-year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate Specific Antigen Screening Era.

Mendhiratta N, Lee T, Prabhu V, Llukani E, Lepor H.

Urology. 2015 Jul 8. pii: S0090-4295(15)00635-4. doi: 10.1016/j.urology.2015.05.034. [Epub ahead of print]

PMID:
26163812
3.

Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.

Nguyen-Nielsen M, Liede A, Maegbaek ML, Borre M, Harving N, Hernandez RK, Sørensen HT, Ehrenstein V.

Cancer Epidemiol. 2015 Aug;39(4):623-32. doi: 10.1016/j.canep.2015.05.008. Epub 2015 Jun 19.

PMID:
26100365
4.

Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.

Taneja SS.

J Urol. 2015 Jul;194(1):113-4. doi: 10.1016/j.juro.2015.04.064. Epub 2015 Apr 18. No abstract available.

PMID:
26088223
6.

Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.

Petrioli R, Francini E, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Roviello G.

Anticancer Res. 2015 May;35(5):3097-102.

PMID:
25964601
7.

Analyzing the Association of Polymorphisms in the CRYBB2 Gene with Prostate Cancer Risk in African Americans.

Faruque MU, Paul R, Ricks-Santi L, Jingwi EY, Ahaghotu CA, Dunston GM.

Anticancer Res. 2015 May;35(5):2565-70.

PMID:
25964531
8.

Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study.

Mok Y, Kimm H, Shin SY, Jee SH, Platz EA.

Urology. 2015 May;85(5):1111-6. doi: 10.1016/j.urology.2015.02.014.

PMID:
25917733
9.

cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients With Prostate Cancer.

Kienel A, Porres D, Heidenreich A, Pfister D.

J Urol. 2015 Apr 18. pii: S0022-5347(15)03827-6. doi: 10.1016/j.juro.2015.04.055. [Epub ahead of print]

PMID:
25896555
10.

Response.

Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv111. doi: 10.1093/jnci/djv111. Print 2015 Jun. No abstract available.

PMID:
25888717
11.

Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Noordzij MA, Blanker MH.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv110. doi: 10.1093/jnci/djv110. Print 2015 Jun. No abstract available.

PMID:
25888716
12.

Tumor expression of adiponectin receptor 2 and lethal prostate cancer.

Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2015 Jun;36(6):639-47. doi: 10.1093/carcin/bgv048. Epub 2015 Apr 11.

PMID:
25863129
13.

Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.

Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, Imamoto T, Suzuki H, Nagata M, Nihei N, Akakura K, Ichikawa T.

J Urol. 2015 Apr 7. pii: S0022-5347(15)03695-2. doi: 10.1016/j.juro.2015.03.120. [Epub ahead of print]

PMID:
25861958
14.

Prostate-specific antigen-based screening: controversy and guidelines.

Kim EH, Andriole GL.

BMC Med. 2015 Mar 24;13:61. doi: 10.1186/s12916-015-0296-5.

15.

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA.

Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003. Epub 2015 Mar 17.

PMID:
25794605
16.

Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean.

Bae JM.

Epidemiol Health. 2015 Mar 7;37:e2015015. doi: 10.4178/epih/e2015015. eCollection 2015.

19.

Four flawed arguments against prostate-specific antigen screening (and 1 good one).

Vickers AJ.

Urology. 2015 Mar;85(3):491-4. doi: 10.1016/j.urology.2014.11.003.

PMID:
25733258
20.

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.

Wu G, Huang S, Nastiuk KL, Li J, Gu J, Wu M, Zhang Q, Lin H, Wu D.

Prostate. 2015 May;75(7):777-82. doi: 10.1002/pros.22967. Epub 2015 Mar 1.

PMID:
25731771
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk